



**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/EA/2024-25/145

December 24, 2024

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - Biocon</b>

**Subject: Notification to Stock Exchanges**

Dear Sir/Madam,

*This is to inform you that the Company has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (US FDA), for our API facility (Site 1), located at Bengaluru, Karnataka, and the inspection stands closed as per 21 CFR20.64(d)(3).*

*This is based on a surveillance inspection conducted by the agency between the 16<sup>th</sup> to 20<sup>th</sup> of September, 2024.*

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary and Compliance Officer**  
**Membership No.: ACS 18776**